Market Intelligence, Clinical Progress, and High-Purity Reagents for Myeloid Neoplasms and Rare Disease Research.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for SETBP1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | SETBP1 Functional Domain (WT & Mutants I871T/D868N) High purity (>90%), Endotoxin Controlled. Sequence Verified. Sf9 Insect Cell / E. coli expressed. |
View SETBP1 Products |
| Gene Delivery | SETBP1 Promise-ORF / Lentivirus Full-length ORF (WT and Degron Mutants) for stable cell line generation. |
View SETBP1 Products |
| Benchmark Ab | Anti-SETBP1 Recombinant Antibody Sequence-verified positive control for Western Blot, IHC, and IP. |
View SETBP1 Products |
| Validator | SETBP1 siRNA Set Target-specific knockdown verification in myeloid leukemia cell lines. |
View SETBP1 Products |
| Related Target A | SET (SET Nuclear Proto-Oncogene) Direct binding partner of SETBP1; protects SET from protease degradation. |
View SET Products |
| Related Target B | PP2A (Protein Phosphatase 2A) Downstream effector; inhibited by the SETBP1-SET complex, driving oncogenesis. |
View PP2A Products |
| Related Target C | MECOM (EVI1) Transcription factor directly upregulated by SETBP1 activation. |
View MECOM Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Mutation-specific binding evaluation (SGS vs. WT) | Recombinant SETBP1 hotspot mutant proteins (I871T, D868N, G870S) sequence-verified by Mass Spec. |
| Intracellular PPI screening (SETBP1-SET complex) | Highly purified, low-endotoxin functional domains preserving native binding interfaces. |
| Lack of Controls | Sequence-defined recombinant antibodies and validated positive control plasmids included |
| False Positives in Knockdown | Chemically modified siRNA pools designed for minimal off-target effects |
Live SETBP1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for SETBP1 therapeutics is intensifying, with major players shifting focus from traditional broad-spectrum tyrosine kinase inhibitors to targeted protein degradation (PROTACs) and small-molecule protein-protein interaction (PPI) disruptors. As first-generation direct inhibitors enter preclinical validation, the next wave of R&D is targeting the disruption of the SETBP1-SET-PP2A signaling axis to restore PP2A tumor suppressor activity in leukemia.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| PROTAC / Degrader | Academic Consortia, Biotech Startups | aCML, JMML, sAML | Degradation kinetics assay (Requires Lentivirus for stable expression of tagged SETBP1) |
| Small Molecule PPI | Preclinical Stage Biopharma | Myeloid Neoplasms, MDS | Disruption assay (Requires high-purity SETBP1 and SET recombinant proteins) |
| Gene Therapy / RNAi | Rare Disease Foundations, Gene Therapy Developers | Schinzel-Giedion Syndrome (SGS) | Expression rescue and knockdown validation (Requires sequence-verified siRNA and ORF Lentivirus) |